Cue Biopharma (CUE) Competitors $0.69 +0.02 (+2.91%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$0.70 +0.01 (+0.87%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE vs. PRQR, NBTX, YMAB, IMAB, CRDF, INBX, MDWD, SOPH, MNPR, and SCPHShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include ProQR Therapeutics (PRQR), Nanobiotix (NBTX), Y-mAbs Therapeutics (YMAB), I-Mab (IMAB), Cardiff Oncology (CRDF), Inhibrx Biosciences (INBX), MediWound (MDWD), SOPHiA GENETICS (SOPH), Monopar Therapeutics (MNPR), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. Its Competitors ProQR Therapeutics Nanobiotix Y-mAbs Therapeutics I-Mab Cardiff Oncology Inhibrx Biosciences MediWound SOPHiA GENETICS Monopar Therapeutics scPharmaceuticals ProQR Therapeutics (NASDAQ:PRQR) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability. Do analysts prefer PRQR or CUE? ProQR Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 275.59%. Cue Biopharma has a consensus target price of $3.00, suggesting a potential upside of 333.53%. Given Cue Biopharma's higher probable upside, analysts plainly believe Cue Biopharma is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PRQR or CUE more profitable? ProQR Therapeutics has a net margin of -157.04% compared to Cue Biopharma's net margin of -507.87%. ProQR Therapeutics' return on equity of -53.49% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets ProQR Therapeutics-157.04% -53.49% -22.07% Cue Biopharma -507.87%-228.43%-114.66% Does the media favor PRQR or CUE? In the previous week, ProQR Therapeutics had 8 more articles in the media than Cue Biopharma. MarketBeat recorded 12 mentions for ProQR Therapeutics and 4 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.68 beat ProQR Therapeutics' score of 0.51 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cue Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, PRQR or CUE? ProQR Therapeutics has higher revenue and earnings than Cue Biopharma. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProQR Therapeutics$20.46M10.95-$30.04M-$0.35-6.09Cue Biopharma$9.29M5.61-$40.67M-$0.67-1.03 Which has more risk and volatility, PRQR or CUE? ProQR Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Do insiders and institutionals hold more shares of PRQR or CUE? 32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 10.8% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryProQR Therapeutics beats Cue Biopharma on 11 of the 17 factors compared between the two stocks. Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.67M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-1.0321.3126.1719.90Price / Sales5.61278.47413.55113.66Price / CashN/A41.4736.1356.90Price / Book2.477.518.025.38Net Income-$40.67M-$55.05M$3.15B$248.50M7 Day Performance-12.34%2.07%1.48%2.06%1 Month Performance9.55%4.84%3.66%4.86%1 Year Performance-29.39%5.37%34.68%20.24% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma4.0985 of 5 stars$0.69+2.9%$3.00+333.5%-35.9%$50.67M$9.29M-1.0360PRQRProQR Therapeutics2.1217 of 5 stars$2.04flat$8.00+292.2%+29.5%$214.63M$20.46M-5.83180News CoverageNBTXNanobiotix2.4603 of 5 stars$4.73+4.4%$8.00+69.1%-7.1%$213.34M$39.18M0.00100Gap DownYMABY-mAbs Therapeutics2.9524 of 5 stars$4.51-4.0%$15.60+245.9%-62.5%$212.83M$87.68M-7.05150IMABI-Mab3.0741 of 5 stars$2.42-5.8%$6.00+147.9%+44.9%$209.87M$3.89M0.00380News CoverageCRDFCardiff Oncology1.6866 of 5 stars$3.15flat$9.88+213.5%+72.6%$209.56M$680K-3.4220INBXInhibrx Biosciences1.8312 of 5 stars$14.27-1.1%N/A+16.1%$208.89M$200K0.12166News CoverageGap UpMDWDMediWound1.8364 of 5 stars$19.37+0.6%$31.80+64.2%+22.9%$208.16M$20.22M-9.2780News CoverageSOPHSOPHiA GENETICS2.834 of 5 stars$3.10+0.3%$7.00+125.8%-33.8%$206.06M$65.17M-3.10520Positive NewsMNPRMonopar Therapeutics3.03 of 5 stars$35.78+6.5%$56.50+57.9%+876.7%$205.47MN/A-10.2810Positive NewsGap UpSCPHscPharmaceuticals4.6169 of 5 stars$3.81-1.6%$14.00+267.5%-4.0%$204.30M$36.33M-1.9930Positive News Related Companies and Tools Related Companies ProQR Therapeutics Alternatives Nanobiotix Alternatives Y-mAbs Therapeutics Alternatives I-Mab Alternatives Cardiff Oncology Alternatives Inhibrx Biosciences Alternatives MediWound Alternatives SOPHiA GENETICS Alternatives Monopar Therapeutics Alternatives scPharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUE) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
